Company: STAA
Filing Date: 2025-09-16
Form Type: DEFM14A
Source: 0001193125-25-204396
Chunk: 85

Company: STAAR SURGICAL CO
Filing Date: 2025-09-16
Form: DEFM14A
Chunk 85
---
 the fact that Alcon offered a price of $58.00 per share of STAAR common stock in April 2024 and, in October 2024, it offered a price of $55.00 per share of STAAR common stock plus up to $7.00 pursuant to a contingent value right upon the achievement 
 of certain milestones, which would have afforded STAAR stockholders greater value as compared to the per share Merger Consideration of $28.00 per share;                                                                                                  |

| • |     | the effect that a failure to consummate the Merger, for any reason, could have on the price of STAAR common stock 
 and on the market’s perceptions of STAAR’s prospects, resulting in loss of value to STAAR’s stockholders;         |

| • |     | the provisions of the Merger Agreement that restrict STAAR’s ability to solicit or participate in                                                                                                                                                    
 discussions or negotiations regarding alternative acquisition proposals with third parties, subject to specified exceptions, and that require STAAR to negotiate with Alcon (if Alcon so requests) prior to STAAR being able to terminate the Merger 
 Agreement to accept a Superior Proposal, and the possibility that STAAR’s obligation to pay the Company Termination Fee of $43,425,000 (or $14,475,000 in certain circumstances) to Alcon upon termination of the Merger Agreement could discourage  
 other potential acquirors from making alternative acquisition proposals to acquire STAAR;                                                                                                                                                            |

| • |     | the possibility that the price of STAAR’s common stock has not yet reflected all of the potential benefits                                                                                                                        
 and value to be derived from STAAR’s strategic initiatives, including reductions in operational expenses, new and expanded regulatory approvals for STAAR ICLs, and expansion of STAAR’s manufacturing operations in Switzerland; |

| • |     | the restrictions in the Merger Agreement on STAAR’s ability to conduct its business prior to the                                        
 consummation of the Merger, which could delay or prevent STAAR from pursuing business opportunities that may arise prior to the Merger; |

| • |     | the risks and costs of potential litigation in connection with the execution of the Merger Agreement and the                             
 consummation of the Merger and the other transactions contemplated therein, even if the claims asserted in such litigation are baseless; |

| • |     | the fact that the Merger Consideration will be taxable to STAAR stockholders for U.S. federal income tax 
 purposes;                                                                                                |

| •